

## Original Articles

- 1 - Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. Lefort M, Sharmin S, Andersen JB, Vukusic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, De Sèze J, Maillart E, Zephir H, Labauge P, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Maurousset A, Ben Nasr H, Hankiewicz K, Pottier C, Maubeuge N, Dimitri-Boulos D, Nifle C, Laplaud DA, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Eichau S, Ozakbas S, Patti F, Onofrij M, Lugaresi A, Terzi M, Grammond P, Grand'Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Shaygannejad V, Prevost J, Maimone D, Skibina O, Buzzard K, Van der Walt A, Karabudak R, Van Wijmeersch B, Csepany T, Spitaleri D, Vucic S, Koch-Henriksen N, Sellebjerg F, Soerensen PS, Hilt Christensen CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Butzkueven H, Magyari M, Kalincik T, Leray E. **2022** *BMC Med Res Methodol*. PMID [35637426](#)
- 2 - Machine learning-driven identification of drugs inhibiting cytochrome P450 2C9. Goldwasser E, Laurent C, Lagarde N, Fabrega S, Nay L, Villoutreix BO, Jelsch C, Nicot AB, Lorient MA, Miteva MA. **2022** *PLoS Comput Biol*. PMID [35081108](#)
- 3 - Disease modifying therapies and disease activity during pregnancy and postpartum in a contemporary cohort of relapsing Multiple Sclerosis patients. Lescot L, Lefort M, Leguy S, Le Page E, Vukusic S, Edan G, Kerbrat A, Lebrun-Frenay C, De Sèze J, Laplaud DA, Wiertlewski S, Leray E, Michel L. **2022** *Mult Scler Relat Disord*. PMID [36037756](#)
- 4 - Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study. Callens A, Leblanc S, Le Page E, Edan G, Jourdain A, Coustans M, Wiertlewski S, Laplaud D, Videt D, Lallement F, Leray E, Michel L. **2022** *Mult Scler Relat Disord*. PMID [35908450](#)
- 5 - Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal. Rollot F, Couturier J, Casey R, Wiertlewski S, Debouverie M, Pelletier J, De Sèze J, Labauge P, Ruet A, Thouvenot E, Ciron J, Berger E, Gout O, Clavelou P, Stankoff B, Casez O, Bourre B, Zephir H, Moreau T, Lebrun-Frenay C, Maillart E, Edan G, Neau JP, Montcuquet A, Cabre P, Camdessanché JP, Defer G, Nasr HB, Maurousset A, Hankiewicz K, Pottier C, Leray E, Vukusic S, Laplaud DA. **2022** *Neurotherapeutics*. PMID [35217934](#)
- 6 - COPP-MS: Corticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients. Leguy S, Lefort M, Lescot L, Michaud A, Vukusic S, Le Page E, Edan G, Kerbrat A, Lebrun-Frenay C, De Sèze J, Laplaud DA, Wiertlewski S, Leray E, Michel L. **2022** *J Neurol*. PMID [35737108](#)
- 7 - Immune status of the murine 22q11.2 deletion syndrome model. Crockett AM, Kebir H, Benallegue N, Adelman P, Gur RE, Sullivan K, Anderson SA, Alvarez JI. **2022** *Eur J Immunol*. PMID [36337041](#)
- 8 - Multiple Sclerosis CSF Is Enriched With Follicular T Cells Displaying a Th1/Eomes Signature. Morille J, Mandon M, Rodriguez S, Roulois D, Leonard S, Garcia A, Wiertlewski S, Le Page E, Berthelot L, Nicot A, Mathé C, Lejeune F, Tarte K, Delaloy C, Amé P, Laplaud D, Michel L. **2022** *Neurol Neuroimmunol Neuroinflamm*. PMID [36266053](#)
- 9 - Patients With Severe Multiple Sclerosis Exhibit Functionally Altered CD8+ Regulatory T Cells. Benallegue N, Nicol B, Lasselin J, Bézie S, Flippe L, Regue H, Vimond N, Remy S, Garcia A, Le Frère F, Anegon I, Laplaud D, Guillonnet C. **2022** *Neurol Neuroimmunol Neuroinflamm*. PMID [36266052](#)
- 10 - Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. Roos I, Malpas C, Leray E, Casey R, Horakova D, Havrdova EK, Debouverie M, Patti F, De Seze J, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Ozakbas S, Grammond P, Zephir H, Ciron J, Maillart E, Moreau T, Amato MP, Labauge P, Alroughani R, Buzzard K, Skibina O, Terzi M, Laplaud DA, Berger E,

Grand'Maison F, Lebrun-Frenay C, Cartechini E, Boz C, Lechner-Scott J, Clavelou P, Stankoff B, Prevost J, Kappos L, Pelletier J, Shaygannejad V, Yamout BI, Khoury SJ, Gerlach O, Spitaleri DLA, Van Pesch V, Gout O, Turkoglu R, Heinzlef O, Thouvenot E, McCombe PA, Soysal A, Bourre B, Slee M, Castillo-Trivino T, Bakchine S, Ampapa R, Butler EG, Wahab A, Macdonell RA, Aguera-Morales E, Cabre P, Ben NH, Van der Walt A, Laureys G, Van Hijfte L, Ramo-Tello CM, Maubeuge N, Hodgkinson S, Sánchez-Menoyo JL, Barnett MH, Labeyrie C, Vucic S, Sidhom Y, Gouider R, Csepany T, Sotoca J, de Gans K, Al-Asmi A, Fragoso YD, Vukusic S, Butzkueven H, Kalincik T; MSBase; OFSEP. **2022** *Neurology*. PMID [35977837](#)

11 - Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study. Levrout M, Laurent-Chabalier S, Ayrignac X, Bigaut K, Rival M, Squalli S, Zéphir H, Alberto T, Pekar JD, Ciron J, Biotti D, Puissant-Lubrano B, Camdessanché JP, Tholance Y, Casez O, Toussaint B, Marion J, Moreau T, Lakomy D, Thomasset A, Maillart E, Sterlin D, Maurousset A, Rocher A, Laplaud DA, Bigot-Corbel E, Bertho PO, Pelletier J, Boucraut J, Labauge P, Vincent T, De Sèze J, Jahn I, Seitz-Polski B, Thouvenot E, Lebrun-Frenay C; Société Francophone de la Sclérose En Plaques (SFSEP). **2022** *Neurol Neuroimmunol Neuroinflamm*. PMID [36376096](#)

12 - Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study. Wilson S, Calocer F, Rollet F, Fauvernier M, Remontet L, Tron L, Vukusic S, Le Page E, Debouverie M, Ciron J, Ruet A, De Sèze J, Zéphir H, Moreau T, Lebrun-Frény C, Laplaud DA, Clavelou P, Labauge P, Berger E, Pelletier J, Heinzlef O, Thouvenot E, Camdessanché JP, Leray E, Dejardin O, Defer G. **2022** *Lancet Reg Health Eur*. PMID [36426377](#)

13 - Multiple sclerosis clinical decision support system based on projection to reference datasets. Ed-Driouch C, Chéneau F, Simon F, Pasquier G, Combès B, Kerbrat A, Le Page E, Limou S, Vince N, Laplaud DA, Mars F, Dumas C, Edan G, Gourraud PA. **2022** *Ann Clin Transl Neuro*. PMID [36412095](#)

14 - Semi-supervised clustering of quaternion time series: Application to gait analysis in multiple sclerosis using motion sensor data. Drouin P, Stamm A, Chevreuil L, Graillot V, Barbin L, Gourraud PA, Laplaud DA, Bellanger L. **2022** *Stat Med*. PMID [36509423](#)

15 - Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference. Gavaille A, Rollot F, Casey R, Debouverie M, Le Page E, Ciron J, De Seze J, Ruet A, Maillart E, Labauge P, Zéphir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanche JP, Maurousset A, Moulin S, Ben NH, Boulos DD, Hankiewicz K, Neau JP, Pottier C, Nifle C, Rabilloud M, Subtil F, Vukusic S; Observatoire Français de la Sclérose en Plaques (OFSEP) Investigators. **2022** *Neurology*. PMID [36564207](#)

16 - Intravenous acetaminophen with morphine versus intravenous morphine alone for acute pain in the emergency room: protocol for a multicenter, randomized, placebo-controlled, double-blinded study (ADAMOPA). Cattin G, Jenvrin J, Hardouin JB, Longo C, Montassier E. **2022** *Trials*. PMID [36522767](#)

17 - Identification of Novel Genetic Risk Factors for Focal Segmental Glomerulosclerosis in Children: Results From the Chronic Kidney Disease in Children (CKiD) Cohort. Durand A, Winkler CA, Vince N, Douillard V, Geffard E, Binns-Roemer E, Ng DK, Gourraud PA, Reidy K, Warady B, Furth S, Kopp JB, Kaskel FJ, Limou S. **2022** *Am J Kidney Dis*. PMID [36623684](#)

## Review, Editorial, Comments

1 - Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study. Manchon E, Laplaud D, Vukusic S, Labauge P, Moreau T, Kobelt G, Grouin JM, Lotz M, Pau D, Christine LF. **2022** *Mult Scler Relat Disord*. PMID [36007299](#)

2 - Microbiota, IgA and Multiple Sclerosis. Boussamet L, Rajoka MSR, Berthelot L. **2022** *Microorganisms*. PMID [35336190](#)

3 - Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society. Vukusic S, Carra-Dalliere C, Ciron J, Maillart E, Michel L, Leray E, Guennoc AM, Bourre B, Laplaud D, Androdias G, Bensa C, Bigaut K, Biotti D, Branger P, Casez O, Cohen M, Daval E, Deschamps R, Donze C, Dubessy AL, Dulau C, Durand-Dubief F, Guillaume M, Hebant B, Kremer L, Kwiatkowski A, Lannoy J, Maarouf A, Manchon E, Mathey G, Moisset X, Montcuquet A, Pique J, Roux T, Marignier R, Lebrun-Frenay C. **2022** *Mult Scler*. PMID [36317497](#)

4 - Single-Cell Analysis to Better Understand the Mechanisms Involved in MS. Dugast E, Shah S, Laplaud DA. **2022** *Int J Mol Sci*. PMID [36292995](#)

- 5 - Pharmacogenetics of human sulfotransferases and impact of amino acid exchange on Phase II drug metabolism. Isvoran A, Peng Y, Ceauranu S, Schmidt L, Nicot AB, Miteva MA. **2022** *Drug Discov Today*. PMID [36096358](#)
- 6 - Editorial: Structure, isotypes, targets, and post-translational modifications of immunoglobulins and their role in infection, inflammation and autoimmunity, Volume II. Novak J, Berthelot L, Hermouet S. **2022** *Front Immunol*. PMID [36325328](#)
- 7 - Neuroinflammation: Extinguishing a blaze of T cells. Benallegue N, Kebir H, Alvarez JI. **2022** *Immunol Rev*. PMID [35909230](#)
- 8 - Formes cliniques et physiopathologie de la sclérose en plaques [Clinical forms and pathophysiology of multiple sclerosis]. Shah S, Laplaud DA. **2022** *Rev Prat*. PMID [35638978](#)